CA 125 Levels and Survival in Ovarian Cancer
Author Information
Author(s): Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M
Primary Institution: Department of Obstetrics and Gynecology, Lainz Medical Center, Vienna, Austria
Hypothesis
Does CA 125 regression after chemotherapy predict long-term survival in patients with advanced ovarian cancer?
Conclusion
CA 125 regression is a temporary prognostic factor for survival in women with advanced ovarian cancer, but it is not reliable for predicting long-term outcomes.
Supporting Evidence
- CA 125 regression was found to be an independent prognostic factor for survival.
- The hazard ratio for CA 125 regression was 1.70.
- A strong time-dependent effect was observed with a hazard ratio of more than 6 immediately after chemotherapy.
Takeaway
Doctors looked at a blood test called CA 125 to see if it could help predict how long women with advanced ovarian cancer would live after treatment. They found it was helpful at first, but not for a long time.
Methodology
CA 125 blood samples were collected before surgery and after two cycles of chemotherapy, and analyzed using a Cox proportional hazards model.
Limitations
The predictive power of CA 125 for long-term survival is temporary and less precise for individual outcomes.
Participant Demographics
Women with advanced ovarian cancer.
Statistical Information
P-Value
0.0001
Confidence Interval
1.32–2.19
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website